Riluzole

Drug Profile

Riluzole

Alternative Names: PK 26124; Rilutek; RP 54274

Latest Information Update: 09 Apr 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Benzothiazoles; Neuroprotectants; Small molecules; Thiazoles
  • Mechanism of Action Glutamate receptor antagonists; Glutamate-release-inhibitors; Voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Amyotrophic lateral sclerosis
  • No development reported Anxiety disorders
  • Discontinued Parkinson's disease; Psychotic disorders

Most Recent Events

  • 09 Apr 2013 No development reported - Preclinical for Anxiety disorders in USA (PO)
  • 04 Apr 2013 Riluzole licensed to Covis Pharma in USA
  • 06 Aug 2012 Launched for Amyotrophic lateral sclerosis in Australia (PO) before Aug 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top